Double doses of clopidogrel better than standard doses for angioplasty patients
This article was originally published in Clinica
Executive Summary
High doses of the antiplatelet drug clopidogrel significantly reduce complications in patients undergoing angioplasty, a trial reported at the ESC meeting has found. The CURRENT-OASIS 7 study assessed 17,000 patients who underwent angioplasty having been randomly assigned to receive either the high dose: 600mg of clopidogrel on the first day, then 150mg once a day for seven days, followed by 75mg daily until day 30, or the low dose: 300mg on day one, followed by 75mg once a day until day 30. The more intensive regimen reduced the risk of stent thrombosis and heart attack by 30% and 22%, respectively, compared with the standard regimen in 68% of patients. There was an increase in major bleeding, but no increase in bleeds into the brain or those that were fatal.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?